TIDMVRCI

RNS Number : 7402F

Verici Dx PLC

20 July 2021

Verici Dx plc

("Verici Dx" or the "Company")

Verici expands its clinical trial by opening first site in Europe

Multi-centre validation trial for leading products on track for completion by the end of the year

including participation from European sites

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has initiated its first European clinical validation trial site with Prof. Gaetano La Manna, Director of the Specialization School in Nephrology and the Dialysis and Transplant Unit, at the Sant'Orsola Polyclinic Hospital in Bologna, Italy.

The trial is a global, non-randomised, observational study for the clinical validation of Verici Dx's lead products, Clarava (TM) to predict risk of early acute rejection in the first six months post-transplant and Tuteva (TM) for the diagnosis of acute cell-mediated rejection, and over the longer term, for the validation of the Company's fibrosis test, now called Protega(TM).

Prof. Gaetano La Manna is the Director of the Nephrology, Dialysis and Transplantation Unit at the IRCCS-Sant'Orsola Polyclinic Hospital; he is Director of the School of Specialization in Nephrology of the University of Bologna; Full Professor of Nephrology at the University of Bologna, as well as Deputy Coordinator and member of the Board of Professors of the Research Doctorate in Cardio-Nephro-Thoracic Sciences. Prof. La Manna holds a PhD in Nephrology and Post-Doctorate in Medical Sciences. He has extensive experience in both clinical and experimental nephrology, dialysis and kidney transplantation, and also in the medical management of kidney transplant and its complications. The Kidney Transplant Center of the University of Bologna, inside the IRCCS Sant'Orsola Polyclinic Hospital, is one of the most important in Europe for number, quality and complexity of transplants, with more than 3,000 to its credit, including donation after brainstem death (DBD), donation after circulatory death (DCD), marginal donor, double transplants, ABO incompatible, hyperimmunized patients, combined kidney-liver, kidney-heart transplants and other special programs.

Angela Rose, Senior Director of Clinical Trial Operations of Verici Dx, said:

"The team has worked incredibly hard on this project, from designing and developing the approach to implementing the trial. In our effort to expand our clinical development and validation beyond North America, we are pleased to be working with Prof. Gaetano La Manna, a highly respected and experienced primary investigator, to lead our trial in Bologna, Italy. The diversification of our patient sample is a strategically important initiative for Verici, as we seek to leverage our clinical expertise and demonstrate our commitment to the development of globally validated transplant diagnostics."

Verici Dx announced the collaboration with three leading US centres for clinical validation trial of its lead products in March 2021 and has subsequently opened 2 more US centres. Enrolment is on target for completion of the Clarava(TM) and Tuteva(TM) validation study by the end of 2021. Data is expected to be published as soon as practicably possible in 2022.

Enquiries:

 
Verici Dx                                                             www.v ericidx .com 
Sara Barrington, CEO                                                     Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated Adviser                             Tel: 020 7496 3000 
 & Broker) 
Aubrey Powell / Justin McKeegan / Tom 
 Salvesen 
 
Walbrook PR Limited                        Tel: 020 7933 8780 or vericidx@walbrookpr.com 
Paul McManus / Sam Allen                              Mob: 07980 541 893 / 07748 651 727 
 

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFZGMNNLZGMZM

(END) Dow Jones Newswires

July 20, 2021 02:00 ET (06:00 GMT)

Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Verici Dx.
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Verici Dx.